EACS2023: 334 Dual therapy with DTG+3TC or DTG+RPV vs. triple therapy with B/F/TAF in virologically suppressed adults living with HIV-1: ummunological outcomes in real-life experience J. Troya , L. Buzón , G. Pousada , R. Micán , C. Galera , J. Sanz , I. Santos , C. Dueñas , N. Cabello , C. Martín , M.J. Galindo , M.Á. Garcinuño , R. Pedrero-Tomé , D. Ortega , M. Matarranz , RETROBIC Hospital Universitario Infanta Leonor, Madrid, Spain, Hospital de Burgos, Burgos, Spain, Hospital Álvaro Cunqueiro, Vigo, Spain, Hospital Universitario La Paz, Madrid, Spain, Hospital L´Arrixaca Murcia, Murcia, Spain, Hospital Príncipe de Asturias, Madrid, Spain, Hospital Universitario La Princesa. CIBERINFEC Instituto de Salud Carlos III, Madrid, Spain, Hospital de Valladolid, Valladolid, Spain, Hospital Clínico de Madrid, Madrid, Spain, Complejo Asistencial de Zamora, Zamora, Spain, Hospital Clínico de Valencia, Valencia, Spain, Complejo Asistencial de Ávila, Ávila, Spain, Fundación de Investigación e Innovación del Hospital Universitario Infanta Leonor y del Sureste, Madrid, Spain General data Abstract category: Antiretroviral therapy – observational studies Abstract body Purpose: Immune recovery in people living with HIV (PLWH) is a residual aspect of antiretroviral treatment in most patients, but in a non-negligible proportion of them, the CD4+ count, or CD4/CD8 ratio, remains suboptimal. Data regarding comparative immunological restoration in triple versus dual therapy is scarce with modern strategies. Method: This study aimed to compare real-life data of three multicenter Spanish cohorts of PLWH using triple therapy with B/F/TAF versus dual therapy with DTG plus 3TC or DTG plus RPV, as switching strategies in virologically controlled patients, not only in terms of virological suppression and durability but also in terms of immune restoration. Results: The study comprised 3759 persons of three retrospective, multicenter cohorts of virologically suppressed PLWH who switched to B/F/TAF (1967), DTG+RPV (760), or DTG+3TC (1032). Characteristics are described in Table. The virological suppression rates were 95.6%, 94.2%, and 97.5% at week 48, respectively (p<0.001). The proportion of patients with virological failure over week 48 was below 1%, with no resistance mutations. Regarding immune recovery, we found a reduction in CD8+ counts with BIC/FTC/TAF, -25.5 [-242.3 – 144.0] and DTG+3TC, -10.5 [-147.5–133.5], (p < 0.001) and an increase in CD4+ count at week 48 with all strategies B/F/TAF, 38.6 [-100.9 – 163.0] DTG+RPV, 21.0 [-87.0–137.0], and DTG+3TC, 49.0 [- 74.0–160.0]), p = 0.016, and an increase in CD4/CD8 ratio in B/F/TAF, 0.05 [-0.05–0.10], DTG+RPV, 0.02 [-0.06 – 0.11], and DTG+3TC, 0-04 [-0.05 – 0.13]), p =<0.001. In AIDS-diagnosed patients, we found no significant differences in CD4+ increase, CD8+ decrease, or CD4/CD8 ratio. Conclusions: Current oral dual or triple therapy strategies presented high rates of virological control at week 48 after switching. B/F/TAF achieved a slight but significant improvement of CD8 and CD4/CD8 with respect to dual therapies. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1 2 3 4 5 6 7 8 9 10 11 12 13 4 1 1 2 3 4 5 6 7 8 9 10 11 12 13 102 19TH EUROPEAN AIDS CONFERENCE | WARSAW 2023
RkJQdWJsaXNoZXIy Mzc2ODc=